Medpace manages clinical trials for small biotech companies.
Medpace Holdings, Inc. (MEDP) is expected to report earnings on Wednesday, October 21, 2026, after the close. Estimated release time 16:15 ET. Consensus EPS estimate is $4.44.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-22 | Jun 2026 qtr | $3.98 | $4.25 | +6.8% | $707.33M |
| 2026-04-22 | Mar 2026 qtr | $3.92 | $4.28 | +9.2% | $706.60M |
| 2026-02-09 | Dec 2025 qtr | $4.19 | $4.67 | +11.5% | $708.45M |
| 2025-10-22 | Sep 2025 qtr | $3.53 | $3.86 | +9.3% | $659.90M |
| 2025-07-21 | Jun 2025 qtr | $2.98 | $3.10 | +4.0% | $603.31M |
| 2025-04-21 | Mar 2025 qtr | $3.06 | $3.67 | — | $558.57M |
| 2025-02-10 | Dec 2024 qtr | $2.96 | $3.67 | — | $536.59M |
| 2024-10-21 | Sep 2024 qtr | $2.78 | $3.01 | +8.3% | $533.32M |
MEDP has beaten consensus EPS in 6 of its last 6 scored quarters.
See MEDP on the live calendar →